289 related articles for article (PubMed ID: 35572596)
1. Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications.
Wanderley CWS; Correa TS; Scaranti M; Cunha FQ; Barroso-Sousa R
Front Immunol; 2022; 13():816642. PubMed ID: 35572596
[TBL] [Abstract][Full Text] [Related]
2. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
[TBL] [Abstract][Full Text] [Related]
3. Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment.
Catalano M; Francesco Iannone L; Cosso F; Generali D; Mini E; Roviello G
Expert Opin Ther Targets; 2022 Nov; 26(11):923-936. PubMed ID: 36519314
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
[TBL] [Abstract][Full Text] [Related]
5. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
6. PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance.
Kanev PB; Atemin A; Stoynov S; Aleksandrov R
Semin Oncol; 2024; 51(1-2):2-18. PubMed ID: 37714792
[TBL] [Abstract][Full Text] [Related]
7. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
8. Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer.
Bailey M; Morand S; Royfman R; Lin L; Singh A; Stanbery L; Walter A; Hamouda D; Nemunaitis J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542143
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
10. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
[TBL] [Abstract][Full Text] [Related]
11. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
12. The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
Hunia J; Gawalski K; Szredzka A; Suskiewicz MJ; Nowis D
Front Mol Biosci; 2022; 9():1073797. PubMed ID: 36533080
[TBL] [Abstract][Full Text] [Related]
13. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Kim DS; Camacho CV; Kraus WL
Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
[TBL] [Abstract][Full Text] [Related]
14. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
15. Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance.
Lovsund T; Mashayekhi F; Fitieh A; Stafford J; Ismail IH
Cells; 2023 Jul; 12(14):. PubMed ID: 37508568
[TBL] [Abstract][Full Text] [Related]
16. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
Moutafi M; Economopoulou P; Rimm D; Psyrri A
Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
[TBL] [Abstract][Full Text] [Related]
18. Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations.
Hu J; Liang P; Jin D; Fan R; Xie X; Liu C; Jiang Q; Gao L
Expert Rev Anticancer Ther; 2022 Jul; 22(7):717-723. PubMed ID: 35679134
[TBL] [Abstract][Full Text] [Related]
19. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
20. The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
Wu Z; Cui P; Tao H; Zhang S; Ma J; Liu Z; Wang J; Qian Y; Chen S; Huang Z; Zheng X; Huang D; Hu Y
Clin Med Insights Oncol; 2021; 15():1179554921996288. PubMed ID: 33737855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
